CLAIMS

What is claimed is:

1. **(currently amended)** A compound of Formula (I)



(I)

wherein

X is carbon and Y is nitrogen or X is nitrogen and Y is carbon;

R^1 is hydrogen, $(C_1\text{-}C_6)$alkyl, halogen, or cyano;

R^2 and R^3 are each independently $(CH_2)_n$-aryl or $(CH_2)_n$-heteroaryl, where n is 0, 1 or 2, and where said aryl and said heteroaryl moieties are optionally substituted with one or more substituents;

L is -C(O)- or $-C(R^4)(OR^5)-$, where R^4 is hydrogen or $(C_1\text{-}C_6)$alkyl and R^5 is hydrogen, $(C_1\text{-}C_6)$alkyl, or taken together with R^8 or R^9 is $-CH_2CH_2-$ or $-CH_2C(O)-$;

R^6 and R^7 are each independently hydrogen or $(C_1\text{-}C_6)$alkyl, or R^6 and R^7 taken together form a partially or fully saturated carbocyclic ring; and

R^8 and R^9 are each independently hydrogen, $(C_1\text{-}C_6)$alkyl, $-C(O)(CH_2)_mR^{10}$, $-SO_2(CH_2)_nR^{10}$, or $-(CH_2)_pR^{10}$, where m and n are 0, 1, or 2, p is 0, 1, 2 or 3, and R^{10} is selected from the group consisting of $(C_1\text{-}C_8)$alkyl, a partially or fully saturated cycloalkyl, aryl, heteroaryl, and a partially or fully saturated heterocycle, where said $(C_1\text{-}C_8)$alkyl, said cycloalkyl, said aryl, said heteroaryl and said heterocycle are optionally substituted with one or more substituents; ~~or~~

~~R^8 and R^9 taken together form a partially or fully saturated, 4- to 8-membered heterocyclic ring containing 1 to 3 heteroatoms and optionally substituted with one or more substituents;~~

a pharmaceutically acceptable salt thereof, a prodrug of said compound or said salt, or a solvate or hydrate of said compound, said salt or said prodrug.

2. **(currently amended)** The compound of Claim 1, wherein said compound of Formula (I) is a compound of Formula (IA)



(IA)

wherein

R^1 is hydrogen or $(C_1\text{-}C_6)$alkyl;

R^2 and R^3 are each independently $-(CH_2)_n$-aryl or $-(CH_2)_n$-heteroaryl, where n is 0, 1 or 2, and where said aryl and said heteroaryl moieties are each optionally substituted with one to three substituents; and

R^6 and R^7 are each independently hydrogen or $(C_1\text{-}C_6)$alkyl, or R^6 and R^7 taken together form a partially or fully saturated carbocyclic ring; and

~~R^8 and R^9 taken together form a partially or fully saturated, 5- to 7-membered heterocyclic ring containing 1 to 3 heteroatoms and optionally substituted with one or more substituents;~~

a pharmaceutically acceptable salt thereof, a prodrug of said compound or said salt, or a solvate or hydrate of said compound, said salt or said prodrug.

3. **(withdrawn)** The compound of Claim 2 selected from the group consisting of

1-[5-(4-chloro-phenyl)-1-(2-chloro-phenyl)-4-methyl-1H-pyrazol-3-yl]-2-piperidin-1-yl-ethanone;

1-[5-(4-chloro-phenyl)-1-(2-chloro-phenyl)-4-methyl-1H-pyrazol-3-yl]-2-morpholin-4-yl-ethanone;

1-[5-(4-chloro-phenyl)-1-(2-chloro-phenyl)-4-methyl-1H-pyrazol-3-yl]-2-[4-(1-methyl-1H-pyrrole-2-carbonyl)-piperazin-1-yl]-ethanone;

1-[5-(4-chloro-phenyl)-1-(2-chloro-phenyl)-4-methyl-1H-pyrazol-3-yl]-2-[4-(1-methyl-cyclopropanecarbonyl)-piperazin-1-yl]-ethanone;

N-(1-{2-[5-(4-chloro-phenyl)-1-(2-chloro-phenyl)-4-methyl-1H-pyrazol-3-yl]-2-oxo-ethyl}-piperidin-4-yl)-2,2,2-trifluoro-acetamide;

1-[5-(4-chloro-phenyl)-1-(2-fluoro-phenyl)-4-methyl-1H-pyrazol-3-yl]-2-morpholin-4-yl-ethanone;

1-[5-(4-chloro-phenyl)-1-(2-fluoro-phenyl)-4-methyl-1H-pyrazol-3-yl]-2-piperidin-1-yl-ethanone;

1-[5-(4-chloro-phenyl)-1-(2-fluoro-phenyl)-4-methyl-1H-pyrazol-3-yl]-2-(4-trifluoroacetyl-piperazin-1-yl)-ethanone;

1-[1-(2-chloro-phenyl)-5-(4-chloro-phenyl)-4-methyl-1H-pyrazol-3-yl]-2-pyrrolidin-1-yl-ethanone;

1-[1-(2-chloro-phenyl)-5-(4-chloro-phenyl)-4-methyl-1H-pyrazol-3-yl]-2-[1,4]oxazepan-4-yl-ethanone; and

1-[5-(4-chloro-phenyl)-1-(2-chloro-phenyl)-4-methyl-1H-pyrazol-3-yl]-2-(1-oxa-8-aza-spiro[4.5]dec-8-yl)-ethanone;

a pharmaceutically acceptable salt thereof or a solvate or hydrate of said compound or said salt.

4. **(currently amended)** The compound of Claim 1, wherein said compound of Formula (I) is a compound of Formula (IB)



(IB)

wherein

R^1 is hydrogen or $(C_1\text{-}C_6)$alkyl;

R^2 and R^3 are each independently $-(CH_2)_n$-aryl or $-(CH_2)_n$-heteroaryl, where n is 0, 1 or 2, and where said aryl and said heteroaryl moieties are each optionally substituted with one to three substituents;

R^4 is hydrogen or $(C_1\text{-}C_6)$alkyl;

R^5 is hydrogen or $(C_1\text{-}C_6)$alkyl;

R^6 and R^7 are each independently hydrogen or $(C_1\text{-}C_6)$alkyl, or R^6 and R^7 taken together form a partially or fully saturated carbocyclic ring; and

R^8 and R^9 are each independently hydrogen, $(C_1\text{-}C_6)$alkyl,

$-C(O)(CH_2)_mR^{10}$, $-SO_2(CH_2)_nR^{10}$, or $-(CH_2)_pR^{10}$, where m and n are 0, 1, or 2, p is 0, 1, 2 or 3, and R^{10} is selected from the group consisting of (C_1-C_8)alkyl, a partially or fully saturated cycloalkyl, aryl, heteroaryl, and a partially or fully saturated heterocycle, where said (C_1-C_8)alkyl, said cycloalkyl, said aryl, said heteroaryl and said heterocycle are optionally substituted with one or more substituents, or

~~R^8 and R^9 taken together form a partially or fully saturated, 5- to 7-membered heterocyclic ring containing 1 to 3 heteroatoms and optionally substituted with one or more substituents;~~

a pharmaceutically acceptable salt thereof, a prodrug of said compound or said salt, or a solvate or hydrate of said compound, said salt or said prodrug.

5. **(withdrawn)** The compound of Claim 4 selected from the group consisting of

2-(benzyl-isopropyl-amino)-1-[1-(2-chloro-phenyl)-5-(4-chloro-phenyl)-4-methyl-1H-pyrazol-3-yl]-ethanol;

1-[5-(4-chloro-phenyl)-1-(2-chloro-phenyl)-4-methyl-1H-pyrazol-3-yl]-2-(3,5-dimethyl-piperidin-1-yl)-ethanol;

1-{2-[1-(2-chloro-phenyl)-5-(4-chloro-phenyl)-4-methyl-1H-pyrazol-3-yl]-2-hydroxy-ethyl}-4-isopropylamino-piperidine-4-carboxylic acid amide;

1-[5-(4-chloro-phenyl)-1-(2-chloro-phenyl)-4-methyl-1H-pyrazol-3-yl]-2-(3,3-dimethyl-piperidin-1-yl)-ethanol;

1-[5-(4-chloro-phenyl)-1-(2-chloro-phenyl)-4-methyl-1H-pyrazol-3-yl]-2-piperidin-1-yl-ethanol; and

1-[5-(4-chloro-phenyl)-1-(2-chloro-phenyl)-4-methyl-1H-pyrazol-3-yl]-2-morpholin-4-yl-ethanol;

a pharmaceutically acceptable salt thereof or a solvate or hydrate of said compound or said salt.

6. **(withdrawn)** The compound of Claim 1 wherein said compound of Formula (I) is a compound of Formula (IC)



(IC)

wherein

R^1 is hydrogen or $(C_1\text{-}C_6)$alkyl;

R^2 and R^3 are each independently $-(CH_2)_n$-aryl or $-(CH_2)_n$-heteroaryl, where n is 0, 1 or 2, and where said aryl and said heteroaryl moieties are each optionally substituted with one to three substituents;

R^6 and R^7 are each independently hydrogen or $(C_1\text{-}C_6)$alkyl, or R^6 and R^7 taken together form a partially or fully saturated carbocyclic ring; and

R^9 is hydrogen, $(C_1\text{-}C_6)$alkyl, $-C(O)(CH_2)_mR^{10}$, $-SO_2(CH_2)_nR^{10}$, or $-(CH_2)_pR^{10}$, where m and n are 0, 1, or 2, p is 0, 1, 2 or 3, and R^{10} is selected from the group consisting of $(C_1\text{-}C_8)$alkyl, a partially or fully saturated cycloalkyl, aryl, heteroaryl, and a partially or fully saturated heterocycle, where said $(C_1\text{-}C_8)$alkyl, said cycloalkyl, said aryl, said heteroaryl and said heterocycle are optionally substituted with one or more substituents;

a pharmaceutically acceptable salt thereof, a prodrug of said compound or said salt, or a solvate or hydrate of said compound, said salt or said prodrug.

7. **(withdrawn)** The compound of Claim 6 selected from the group consisting of

2-[5-(4-chloro-phenyl)-1-(2-chloro-phenyl)-4-methyl-1H-pyrazol-3-yl]-4-cyclohexyl-morpholine;

2-[5-(4-chloro-phenyl)-1-(2-chloro-phenyl)-4-methyl-1H-pyrazol-3-yl]-4-(propane-2-sulfonyl)-morpholine;

2-[5-(4-chloro-phenyl)-1-(2-chloro-phenyl)-4-methyl-1H-pyrazol-3-yl]-4-(toluene-4-sulfonyl)-morpholine;

1-{2-[1-(2-chloro-phenyl)-5-(4-chloro-phenyl)-4-methyl-1H-pyrazol-3-yl]-morpholin-4-yl}-2-methyl-propan-1-one;

2-[1-(2-chloro-phenyl)-5-(4-chloro-phenyl)-4-methyl-1H-pyrazol-3-yl]-4-(4-trifluoromethyl-benzyl)-morpholine; and

a pharmaceutically acceptable salt thereof or a solvate or hydrate of said compound or said salt.

8. **(withdrawn)** The compound of Claim 1, wherein said compound of Formula (I) is a compound of Formula (ID)



(ID)

wherein

R^1 is hydrogen or $(C_1\text{-}C_6)$alkyl;

R^2 and R^3 are each independently $-(CH_2)_n$-aryl or $-(CH_2)_n$-heteroaryl, where n is 0, 1 or 2, and where said aryl and said heteroaryl moieties are each optionally substituted with one to three substituents;

R^6 and R^7 are each independently hydrogen or $(C_1\text{-}C_6)$alkyl, or R^6 and R^7 taken together form a partially or fully saturated carbocyclic ring; and

R^8 and R^9 taken together form a partially or fully saturated, 5- to 7-membered heterocyclic ring containing 1 to 3 heteroatoms and optionally substituted with one or more substituents;

a pharmaceutically acceptable salt thereof, a prodrug of said compound or said salt, or a solvate or hydrate of said compound, said salt or said prodrug.

9. **(withdrawn)** The compound of Claim 8 selected from the group consisting of

1-[1-(4-chloro-phenyl)-2-(2,4-dichloro-phenyl)-5-methyl-1H-imidazol-4-yl]-2-piperidin-1-yl-ethanone; and

1-[1-(4-chloro-phenyl)-2-(2,4-dichloro-phenyl)-5-methyl-1H-imidazol-4-yl]-2-morpholin-4-yl-ethanone;

a pharmaceutically acceptable salt thereof or a solvate or hydrate of said compound or said salt.

10. **(original)** The compound of Claim 1, 2, 4, 6, or 8 wherein R^2 is *p*-chlorophenyl or *p*-fluorophenyl, and R^3 is 2,4-dichlorophenyl, 2-chlorophenyl or 2-flurorophenyl.

11. **(original)** A pharmaceutical composition comprising

(a) a compound of Claim 1, a pharmaceutically acceptable salt thereof, or a solvate or hydrate of said compound or said salt; and

(b) a pharmaceutically acceptable excipient, diluent, or carrier.

12. **(canceled)**

13. **(canceled)**

14. **(withdrawn)** A method for treating a disease, condition or disorder modulated by a cannabinoid receptor antagonist in animals comprising the step of administering to an animal in need of such treatment a therapeutically effective amount of a compound of Claim 1, a pharmaceutically acceptable salt thereof, or a solvate or hydrate of said compound or said salt.

15. **(withdrawn)** The method of Claim 14 wherein said cannabinoid receptor is a CB1 receptor.

16. **(withdrawn)** The method of Claim 15 wherein said disease, condition or disorder modulated by a cannabinoid receptor antagonist is selected from the group consisting of weight loss, obesity, bulimia, depression, atypical depression, bipolar disorders, psychoses, schizophrenia, behavioral addictions, suppression of reward-related behaviors, alcoholism, tobacco abuse, memory loss, Alzheimer's disease, dementia of aging, seizure disorders, epilepsy, attention deficit disorder, Parkinson's disease, gastrointestinal disorders, and type II diabetes.

17. **(withdrawn)** The method of Claim 15 wherein said disease is obesity, bulimia, attention deficit disorder, alcoholism, or tobacco abuse.

18. **(withdrawn)** A method for treating a disease, condition or disorder modulated by a cannabinoid receptor antagonist in animals comprising the step of administering to an animal in need of such treatment two separate pharmaceutical compositions comprising

(i) a first composition comprising a compound of Claim 1 and a pharmaceutically acceptable excipient, diluent, or carrier, and

(ii) a second composition comprising at least one additional pharmaceutical agent and a pharmaceutically acceptable excipient, diluent, or carrier.

19. **(withdrawn)** The method of Claim 18 wherein said at least one additional pharmaceutical agent is a nicotine partial agonist, an opioid antagonist, a dopaminergic agent, an attention deficit disorder agent, or an anti-obesity agent.

20. **(withdrawn)** The method of Claim 19 wherein said anti-obesity agent is selected from the group consisting of an apo-B/MTP inhibitor, a 11β-hydroxy steroid dehydrogenase-1 inhibitor, peptide YY_{3-36} or an analog thereof, a MCR-4 agonist, a CCK-A agonist, a monoamine reuptake inhibitor, a sympathomimetic agent, a β_3 adrenergic receptor agonist, a dopamine agonist, a melanocyte-stimulating hormone receptor analog, a 5-HT2c receptor agonist, a melanin concentrating hormone antagonist, leptin, a leptin analog, a leptin receptor agonist, a galanin antagonist, a lipase inhibitor, a bombesin agonist, a neuropeptide-Y receptor antagonist, a thyromimetic agent, dehydroepiandrosterone or analog thereof, a glucocorticoid receptor antagonist, an orexin receptor antagonist, a glucagon-like peptide-1 receptor agonist, a ciliary neurotrophic factor, a human agouti-related protein antagonist, a ghrelin receptor antagonist, a histamine 3 receptor antagonist or inverse agonist, and a neuromedin U receptor agonist.

21. **(withdrawn)** The method of Claim 18 wherein said first composition and said second composition are administered simultaneously.

22. **(withdrawn)** The method of Claim 18 wherein said first composition and said second composition are administered sequentially and in any order.

23. **(withdrawn)** The method of Claim 18, 19, 20, 21, or 22 wherein said disease is obesity, bulimia, attention deficit disorder, alcoholism, or tobacco abuse.

24. **(new)** The compound selected from the group consisting of

2-(Benzyl-isopropyl-amino)-1-[1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methyl-1H-pyrazol-3-yl]-ethanone hydrochloride salt;

2-(Benzyl-isopropyl-amino)-1-[1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methyl-1H-pyrazol-3-yl]-ethanol;

2-(Benzyl-isopropyl-amino)-1-[1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methyl-1H-pyrazol-3-yl]-ethanol hydrochloride;

2-[Benzyl-(2-hydroxy-ethyl)-amino]-1-[5-(4-chlorophenyl)-1-(2-chlorophenyl)-4-methyl-1H-pyrazol-3-yl]-ethanol;

1-Benzylamino-1-[5-(4-chlorophenyl)-1-(2-chlorophenyl)-4-methyl-1H-pyrazol-3-yl]-ethanol hydrochloride;

benzyl-{2-[1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methyl-1H-pyrazol-3-yl]-2-methoxy-ethyl}-isopropyl-amine; and

1-(Benzyl-isopropyl-amino)-2-[1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methyl-1H-pyrazol-3-yl]-propan-2-ol;

or a pharmaceutically acceptable salt thereof or a solvate or hydrate of said compound or said salt.